

RECEIVED
CENTRAL FAX CENTER

NOV 12 2008

Application Serial No.: 10/533,371
Amendment and Response dated 11 November 2008
Reply to Office Action of July 11, 2008
Page 3 of 7

wherein said therapeutically effective amount is sufficient to increase the rate of IGFBP-1 expression as to at least increase the rate of liver-damage resolution over the rate of liver-damage progression.


20. (Original) The method according to claim 19 wherein the compound is halofuginone.

21-26. (Canceled)

27. (New) The method according to claim 19, wherein said administration specifically activates only hepatocyte cells.

28. (New) The method according to claim 19, wherein said administration further induces inhibition of stellate cell mobility.

29. (New) A method for improving liver regeneration by increasing the IGFBP-1 expression in hepatocyte cells comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a compound having the formula:



wherein: $n=1-2$

R_1 is at each occurrence independently selected from the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;

R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; and

Application Serial No.: 10/533,371
Amendment and Response dated 11 November 2008
Reply to Office Action of July 11, 2008
Page 4 of 7

R₃ is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof, wherein said administration is performed early in a liver-damaging process.